Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

525 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults.
Nicholson O, DiCandilo F, Kublin J, Sun X, Quirk E, Miller M, Gray G, Pape J, Robertson MN, Mehrotra DV, Self S, Turner K, Sanchez J, Pitisuttithum P, Duerr A, Dubey S, Kierstead L, Casimiro D, Hammer For The Merck V/Hiv Vaccine Trials Network Study Team SM. Nicholson O, et al. Among authors: pape j. AIDS Res Hum Retroviruses. 2011 May;27(5):557-567. doi: 10.1089/AID.2010.0151. Epub 2010 Nov 23. AIDS Res Hum Retroviruses. 2011. PMID: 20854108 Free PMC article.
The urge for an AIDS vaccine: perspectives from a developing country.
Pape JW, Deschamps MM, Verdier RI, Jean S, Desvarieux M, Taverne G, Gelin C, Hyppolite PR, Denize J, Mellon R, et al. Pape JW, et al. AIDS Res Hum Retroviruses. 1992 Aug;8(8):1535-7. doi: 10.1089/aid.1992.8.1535. AIDS Res Hum Retroviruses. 1992. PMID: 1467000
A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).
Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Grove D, Gray G, Bekker LG, McElrath MJ, Tomaras GD, Goepfert P, Kalams S, Baden LR, Lally M, Dolin R, Blattner W, Kalichman A, Figueroa JP, Pape J, Schechter M, Defawe O, De Rosa SC, Montefiori DC, Nabel GJ, Corey L, Keefer MC; NIAID HIV Vaccine Trials Network. Churchyard GJ, et al. Among authors: pape j. PLoS One. 2011;6(8):e21225. doi: 10.1371/journal.pone.0021225. Epub 2011 Aug 3. PLoS One. 2011. PMID: 21857901 Free PMC article. Clinical Trial.
Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study).
Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Gilbert P, Corey L, Robertson MN; Step/HVTN 504 Study Team. Duerr A, et al. J Infect Dis. 2012 Jul 15;206(2):258-66. doi: 10.1093/infdis/jis342. Epub 2012 May 4. J Infect Dis. 2012. PMID: 22561365 Free PMC article. Clinical Trial.
HIV and AIDS in Haiti: recent developments.
Desvarieux M, Pape JW. Desvarieux M, et al. Among authors: pape jw. AIDS Care. 1991;3(3):271-9. doi: 10.1080/09540129108253073. AIDS Care. 1991. PMID: 1932190 Review.
Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120.
Cleghorn F, Pape JW, Schechter M, Bartholomew C, Sanchez J, Jack N, Metch BJ, Hansen M, Allen M, Cao H, Montefiori DC, Tomaras GD, Gurunathan S, Eastman DJ, do Lago RF, Jean S, Lama JR, Lawrence DN, Wright PF; 026 Protocol Team and the NIAID HIV Vaccine Trials Network. Cleghorn F, et al. Among authors: pape jw. J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):222-30. doi: 10.1097/QAI.0b013e318149297d. J Acquir Immune Defic Syndr. 2007. PMID: 17693888 Clinical Trial.
525 results